Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
Dandona, P.; Mathieu, C.; Phillip, M.et al.
2017 • In The Lancet Diabetes and Endocrinology, 5 (11), p. 864-876
Dandona, P.; Department of Medicine, State University of New York at Buffalo, Buffalo, NY, United States
Mathieu, C.; Clinical and Experimental Endocrinology, UZ Gasthuisberg, University of Leuven, Leuven, Belgium
Phillip, M.; Schneider Children's Medical Center of Israel, Institute for Endocrinology & Diabetes, Petah Tikva, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Hansen, L.; Bristol-Myers Squibb, Princeton, NJ, United States
Griffen, S. C.; JDRF, New York, NY, United States
Tschöpe, D.; Department for Endocrinology, Diabetology & Gastroenterology, Heart and Diabetes Centre, Bad Oeynhausen, Germany, Ruhr University Bochum, Bochum, Germany
Thorén, F.; AstraZeneca, Mölndal, Sweden
Xu, J.; AstraZeneca, Gaithersburg, MD, United States
Langkilde, A. M.; AstraZeneca, Mölndal, Sweden
Proietto, J.
Stranks, S.
Chen, R.
O'Neal, D.
Pape, A.
Forbes, M.
Morbey, C.
Luger, A.
Hanusch, U.
Schnack, C.
Fliesser-Goerzer, E.
Hoelzl, B.
Ebenbichler, C.
Prager, R.
Van Gaal, L.
Vercammen, C.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
Nathan, DM, for the DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 37 (2014), 9–16.
Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 313 (2015), 45–53.
Lind, M, Svensson, A-M, Kosiborod, M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 371 (2014), 1972–1982.
Chen, Z, Miao, F, Paterson, AD, et al. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. Proc Natl Acad Sci USA 113 (2016), E3002–E3011.
Sandahl, K, Nielsen, LB, Svensson, J, et al. Increased mortality in a Danish cohort of young people with Type 1 diabetes mellitus followed for 24 years. Diabet Med 34 (2017), 380–386.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care 33 (2010), 17–22.
Miller, KM, Foster, NC, Beck, RW, et al., for the T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the US: updated data from the T1D Exchange clinic registry. Diabetes Care 38 (2015), 971–978.
Swedish National Diabetes Register. Nationella Diabetesregistret Årsrapport 2015. Göteborg: National Diabetes Register. https://www.ndr.nu/pdfs/Arsrapport_NDR_2015.pdf, 2015 (accessed Aug 26, 2017).
Dandona, P, Kuhadiya, ND, Ghanim, H, Chaudhuri, A, Adjunct therapies in type 1 diabetes. Endocr Pract 22 (2016), 277–280.
Conway, B, Miller, RG, Costacou, T, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med 27 (2010), 398–404.
Evans, JM, Newton, RW, Ruta, DA, MacDonald, TM, Morris, AD, Socio-economic status, obesity and prevalence of type 1 and type 2 diabetes mellitus. Diabet Med 17 (2000), 478–480.
Ridderstråle, M, Gudbjörnsdottir, S, Eliasson, B, Nilsson, PM, Cederholm, J, for the Steering Committee of the Swedish National Diabetes Register (NDR). Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. J Intern Med 259 (2006), 314–322.
Vasilakou, D, Karagiannis, T, Athanasiadou, E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159 (2013), 262–274.
Heerspink, HJL, Perkins, BA, Fitchett, DH, Husain, M, Cherney, DZI, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
Henry, RR, Rosenstock, J, Edelman, S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 38 (2015), 412–419.
Chen, J, Fan, F, Wang, JY, et al. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep, 7, 2017, 44128.
Henry, RR, Dandona, P, Pettus, J, Mudaliar, S, Xu, J, Hansen, L, Dapagliflozin in patients with type 1 diabetes: a post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study. Diabetes Obes Metab 19 (2017), 814–821.
Service, FJ, Molnar, GD, Rosevear, JW, Ackerman, E, Gatewood, LC, Taylor, WF, Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19 (1970), 644–655.
Seaquist, ER, Anderson, J, Childs, B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36 (2013), 1384–1395.
Kitabchi, AE, Umpierrez, GE, Miles, JM, Fisher, JN, Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32 (2009), 1335–1343.
Frandsen, CS, Dejgaard, TF, Madsbad, S, Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. Lancet Diabetes Endocrinol 4 (2016), 766–780.
Purnell, JQ, Hokanson, JE, Marcovina, SM, Steffes, MW, Cleary, PA, Brunzell, JD, Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA 280 (1998), 140–146.
Vella, S, Buetow, L, Royle, P, Livingstone, S, Colhoun, HM, Petrie, JR, The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 53 (2010), 809–820.
Staels, F, Moyson, C, Mathieu, C, Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus. Diabetes Obes Metab, 2017 published online March 20. DOI:10.1111/dom.12948.
Petrie, JR, Chaturvedi, N, Ford, I, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5 (2017), 597–609.
Neal, B, Perkovic, V, Mahaffey, KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
Wanner, C, Inzucchi, SE, Lachin, JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
Fioretto, P, Zambon, A, Rossato, M, Busetto, L, Vettor, R, SGLT2 inhibitors and the diabetic kidney. Diabetes Care 39:suppl 2 (2016), S165–S171.
Sands, AT, Zambrowicz, BP, Rosenstock, J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 38 (2015), 1181–1188.
Pieber, TR, Famulla, S, Eilbracht, J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 17 (2015), 928–935.
Kuhadiya, ND, Ghanim, H, Mehta, A, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. J Clin Endocrinol Metab 101 (2016), 3506–3515.
Peters, AL, Henry, RR, Thakkar, P, Tong, C, Alba, M, Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care 39 (2016), 532–538.
Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 18 (1995), 1415–1427.
Ahrén, B, Hirsch, IB, Pieber, TR, et al., for the ADJUNCT TWO investigators. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care 39 (2016), 1693–1701.
Mathieu, C, Zinman, B, Hemmingsson, JU, et al., for the ADJUNCT ONE Investigators. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 39 (2016), 1702–1710.